ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $16.00 price target on the stock.
Anika Therapeutics Announces Leadership Transition [Yahoo! Finance]
Anika Therapeutics Announces Leadership Transition